Serratus Posterior Superior Intercostal Plane Block Versus Intrathecal Morphine in VATs

April 28, 2026 updated by: Cengiz KAYA, Ondokuz Mayıs University

Comparison of the Effects of Serratus Posterior Superior Intercostal Plane Block and Intrathecal Morphine on Postoperative Acute Pain in Patients Undergoing Video-assisted Thoracoscopic Surgery

This study aims to compare the analgesic effects of the serratus posterior superior intercostal plane block and intrathecal morphine in patients undergoing video-assisted thoracoscopic surgery.

This is a prospective, randomized, controlled, single-center clinical trial including adult patients undergoing elective thoracoscopic surgery. Participants will be randomly assigned to receive either a serratus posterior superior intercostal plane block or intrathecal morphine before general anesthesia.

The primary outcome is cumulative opioid consumption during the first 24 postoperative hours, expressed as intravenous morphine milligram equivalents. Secondary outcomes include pain scores, time to first analgesic request, quality of recovery, and postoperative complications.

The study aims to determine whether these two techniques differ in their effectiveness for postoperative pain management.

Study Overview

Detailed Description

This study is a prospective, randomized, controlled, single-blinded, parallel-group clinical trial designed to compare the analgesic efficacy of serratus posterior superior intercostal plane block and intrathecal morphine in patients undergoing video-assisted thoracoscopic surgery.

Eligible patients aged 18-75 years with American Society of Anesthesiologists physical status I-III scheduled for elective thoracoscopic procedures (wedge resection, segmentectomy, or lobectomy) will be included. Patients will be randomized in a 1:1 ratio using a computer-generated sequence with block randomization.

Participants in the serratus posterior superior intercostal plane block group will receive an ultrasound-guided regional block prior to the induction of general anesthesia. Participants in the intrathecal morphine group will receive an intrathecal morphine injection before general anesthesia. All patients will receive standardized general anesthesia and postoperative patient-controlled analgesia.

The primary outcome is cumulative opioid consumption within the first 24 postoperative hours, expressed as intravenous morphine milligram equivalents.

Secondary outcomes include opioid consumption at 12 hours, numeric rating scale pain scores at rest and during activity, time to first analgesic request, quality of recovery scores, postoperative nausea and vomiting, sedation levels, pruritus, respiratory depression, and postoperative complications up to 30 days.

This study aims to evaluate the relative effectiveness of these two analgesic techniques and to improve postoperative pain management strategies in thoracic surgery.

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Samsun
      • Atakent, Samsun, Turkey (Türkiye), 55270
        • Recruiting
        • Ondokuz Mayis University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age between 18 and 75 years
  • American Society of Anesthesiologists physical status I to III
  • Scheduled for elective video-assisted thoracoscopic surgery including wedge resection, segmentectomy, or lobectomy

Exclusion Criteria:

  • Refusal to participate
  • Pregnancy
  • Morbid obesity (body mass index greater than 40 kg per square meter)
  • Allergy to opioids, local anesthetics, or nonsteroidal anti-inflammatory drugs
  • Neuropsychiatric disorders, cognitive impairment, or inability to communicate
  • History of substance abuse
  • Use of anticoagulant therapy or presence of bleeding disorders
  • Active systemic infection
  • Severe cardiovascular, hepatic, renal, or endocrine disease
  • Chronic pain syndrome or ongoing chronic pain treatment
  • Emergency surgery or prior ipsilateral thoracic surgery
  • Preoperative opioid use
  • Significant intraoperative or postoperative bleeding or hemodynamic instability
  • Requirement for prolonged postoperative mechanical ventilation longer than 18 hours

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intrathecal Morphine
Participants receive intrathecal morphine before induction of general anesthesia. Intrathecal morphine is administered at a dose of 5 micrograms per kilogram in 3 milliliters of saline via spinal injection. All patients subsequently undergo standardized general anesthesia and receive postoperative patient-controlled analgesia with intravenous morphine.
Intrathecal morphine is administered at a dose of 5 micrograms per kilogram diluted in 3 milliliters of saline via spinal injection at the lumbar level before induction of general anesthesia.
Experimental: Serratus Posterior Superior Intercostal Plane Block
Participants receive an ultrasound-guided serratus posterior superior intercostal plane block before induction of general anesthesia. A total of 30 milliliters of 0.25 percent bupivacaine with epinephrine is administered into the interfascial plane between the serratus posterior superior muscle and intercostal muscles. All patients subsequently undergo standardized general anesthesia and receive postoperative patient-controlled analgesia with intravenous morphine.
Ultrasound-guided serratus posterior superior intercostal plane block is performed before induction of general anesthesia using 30 milliliters of 0.25 percent bupivacaine with epinephrine injected into the interfascial plane between the serratus posterior superior muscle and intercostal muscles.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cumulative opioid consumption within 24 hours after surgery
Time Frame: 24 hours
Total opioid consumption during the first 24 postoperative hours is expressed as intravenous morphine milligram equivalents, including patient-controlled analgesia and rescue analgesia.
24 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cumulative opioid consumption within 12 hours after surgery
Time Frame: 12 hours
Total opioid consumption during the first 12 postoperative hours expressed as intravenous morphine milligram equivalents
12 hours
Postoperative pain scores
Time Frame: 0, 3, 6, 12, 18, and 24 hours postoperatively
Pain intensity assessed using the 11-point Numeric Rating Scale (NRS; 0-10), where higher scores indicate greater pain intensity, with 0 representing no pain and 10 representing the worst imaginable pain, measured at rest and during activity.
0, 3, 6, 12, 18, and 24 hours postoperatively
Time to first patient-controlled analgesia demand
Time Frame: 24 hours
Time from arrival in the postoperative period to first patient-controlled analgesia demand
24 hours
Quality of recovery score
Time Frame: Preoperative baseline, 24 hours postoperatively, and at discharge
Quality of recovery assessed using the 15-item Quality of Recovery questionnaire (QoR-15; total score range 0-150), a validated patient-reported outcome measure where higher scores indicate better postoperative recovery.
Preoperative baseline, 24 hours postoperatively, and at discharge
Postoperative nausea and vomiting
Time Frame: 0, 3, 6, 12, 18, and 24 hours postoperatively
Postoperative nausea and vomiting (PONV) assessed using a 4-point ordinal scale (0-3), where 0 indicates no nausea or vomiting, 1 indicates nausea without vomiting, 2 indicates a single episode of vomiting, and 3 indicates multiple episodes of vomiting; higher scores indicate worse symptoms. Rescue antiemetic therapy (intravenous metoclopramide) will be administered for scores >1.
0, 3, 6, 12, 18, and 24 hours postoperatively
Sedation level
Time Frame: 0, 3, 6, 12, 18, and 24 hours postoperatively
Sedation level assessed using the Ramsay Sedation Scale (RSS; 1-6), a validated ordinal scale where higher scores indicate deeper sedation, with 1 representing anxiety/agitation and 6 representing no response to stimuli.
0, 3, 6, 12, 18, and 24 hours postoperatively
Respiratory depression
Time Frame: 24 hours
Incidence of respiratory depression defined as oxygen saturation below 90 percent or respiratory rate below 8 breaths per minute
24 hours
Pruritus
Time Frame: 0, 3, 6, 12, 18, and 24 hours postoperatively
Incidence and severity of postoperative pruritus assessed using a 4-point ordinal scale (0-3), where 0 = no pruritus, 1 = mild pruritus (itching without scratching), 2 = moderate pruritus (itching with scratching), and 3 = severe pruritus requiring treatment; higher scores indicate worse symptoms.
0, 3, 6, 12, 18, and 24 hours postoperatively
Post-dural puncture headache
Time Frame: 30 days
Incidence of headache consistent with post-dural puncture headache
30 days
Postoperative complications
Time Frame: 30 days
Postoperative complications assessed using the Clavien-Dindo classification, where higher grades indicate more severe complications.
30 days
Remifentanil consumption
Time Frame: Intraoperative period (from induction to end of surgery), up to 4 hours
Total intraoperative remifentanil consumption administered during surgery, measured in micrograms (µg).
Intraoperative period (from induction to end of surgery), up to 4 hours
Rescue analgesia requirement
Time Frame: 24 hours
Incidence of patients requiring additional analgesia beyond patient-controlled analgesia
24 hours
Incidence of PONV (postoperative of nausea and/or vomiting)
Time Frame: 24 hours postoperatively
Incidence of postoperative nausea and vomiting (PONV), defined as the occurrence of at least one episode of nausea and/or vomiting within the first 24 hours postoperatively (yes/no). Patients experiencing at least one episode will be classified as having PONV.
24 hours postoperatively
Propofol consumption
Time Frame: Intraoperative period (from induction to end of surgery), up to 4 hours
Total intraoperative propofol consumption administered during surgery, measured in milligrams (mg).
Intraoperative period (from induction to end of surgery), up to 4 hours

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Heart Rate
Time Frame: Intraoperative period (up to 4 hours)
Heart rate measured intraoperatively and postoperatively, expressed in beats per minute (bpm).
Intraoperative period (up to 4 hours)
Mean Arterial Pressure
Time Frame: Intraoperative period (up to 4 hours)
Mean arterial pressure measured intraoperatively and postoperatively, expressed in millimeters of mercury (mmHg).
Intraoperative period (up to 4 hours)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 15, 2026

Primary Completion (Estimated)

September 15, 2026

Study Completion (Estimated)

September 30, 2026

Study Registration Dates

First Submitted

April 9, 2026

First Submitted That Met QC Criteria

April 16, 2026

First Posted (Actual)

April 20, 2026

Study Record Updates

Last Update Posted (Actual)

May 4, 2026

Last Update Submitted That Met QC Criteria

April 28, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Postoperative Pain

Clinical Trials on Intrathecal Morphine

Subscribe